3,678 Shares in Astrazeneca Plc $AZN Bought by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC bought a new position in shares of Astrazeneca Plc (NYSE:AZN) during the first quarter, Holdings Channel reports. The fund bought 3,678 shares of the company’s stock, valued at approximately $725,000.

Other hedge funds have also modified their holdings of the company. Fisher Asset Management LLC boosted its position in shares of Astrazeneca by 2.1% in the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock valued at $3,791,051,000 after purchasing an additional 438,709 shares during the period. Franklin Resources Inc. raised its holdings in Astrazeneca by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after buying an additional 445,014 shares during the period. Morgan Stanley raised its holdings in Astrazeneca by 3.2% during the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after buying an additional 432,939 shares during the period. Royal Bank of Canada lifted its stake in Astrazeneca by 208.6% during the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock valued at $2,048,417,000 after buying an additional 7,021,126 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Astrazeneca by 546.1% during the first quarter. Bank of New York Mellon Corp now owns 6,667,812 shares of the company’s stock valued at $1,315,026,000 after buying an additional 5,635,812 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AZN has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Wall Street Zen cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Stock Performance

Shares of AZN opened at $169.77 on Friday. The firm has a market cap of $263.30 billion, a price-to-earnings ratio of 25.38, a price-to-earnings-growth ratio of 1.47 and a beta of 0.24. The company’s fifty day moving average is $179.02 and its 200-day moving average is $187.80. The company has a quick ratio of 0.71, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. Astrazeneca’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.17 EPS. Equities analysts expect that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.